Terms: = Prostate cancer AND PTEN, MMAC1, 5728, MGC11227, PTEN1, MHAM, P60484, BZS, ENSG00000171862 AND Prognosis
188 results:
1. The impact of telomere length on prostate cancer aggressiveness, genomic instability and health disparities.
Huang R; Bornman MSR; Stricker PD; Simoni Brum I; Mutambirwa SBA; Jaratlerdsiri W; Hayes VM
Sci Rep; 2024 Apr; 14(1):7706. PubMed ID: 38565642
[TBL] [Abstract] [Full Text] [Related]
2. Molecular complexity of intraductal carcinoma of the prostate.
Zhu S; Xu N; Zeng H
Cancer Med; 2024 Jan; 13(2):e6939. PubMed ID: 38379333
[TBL] [Abstract] [Full Text] [Related]
3. New emerging targets in osteosarcoma therapy: pten and PI3K/Akt crosstalk in carcinogenesis.
Sadrkhanloo M; Paskeh MDA; Hashemi M; Raesi R; Bahonar A; Nakhaee Z; Entezari M; Beig Goharrizi MAS; Salimimoghadam S; Ren J; Nabavi N; Rashidi M; Dehkhoda F; Taheriazam A; Tan SC; Hushmandi K
Pathol Res Pract; 2023 Nov; 251():154902. PubMed ID: 37922723
[TBL] [Abstract] [Full Text] [Related]
4. 'High proliferative cribriform prostate cancer' defines a patient subgroup with an inferior prognosis.
Bogaard M; Skotheim RI; Maltau AV; Kidd SG; Lothe RA; Axcrona K; Axcrona U
Histopathology; 2023 Dec; 83(6):853-869. PubMed ID: 37501635
[TBL] [Abstract] [Full Text] [Related]
5. PI3K/Akt signaling in urological cancers: Tumorigenesis function, therapeutic potential, and therapy response regulation.
Rezaei S; Nikpanjeh N; Rezaee A; Gholami S; Hashemipour R; Biavarz N; Yousefi F; Tashakori A; Salmani F; Rajabi R; Khorrami R; Nabavi N; Ren J; Salimimoghadam S; Rashidi M; Zandieh MA; Hushmandi K; Wang Y
Eur J Pharmacol; 2023 Sep; 955():175909. PubMed ID: 37490949
[TBL] [Abstract] [Full Text] [Related]
6. The Genomic and Epigenomic Landscape of Double-Negative Metastatic prostate cancer.
Lundberg A; Zhang M; Aggarwal R; Li H; Zhang L; Foye A; Sjöström M; Chou J; Chang K; Moreno-Rodriguez T; Shrestha R; Baskin A; Zhu X; Weinstein AS; Younger N; Alumkal JJ; Beer TM; Chi KN; Evans CP; Gleave M; Lara PN; Reiter RE; Rettig MB; Witte ON; Wyatt AW; Feng FY; Small EJ; Quigley DA
Cancer Res; 2023 Aug; 83(16):2763-2774. PubMed ID: 37289025
[TBL] [Abstract] [Full Text] [Related]
7. Spatial Gene Expression Analysis Reveals Characteristic Gene Expression Patterns of De Novo Neuroendocrine prostate cancer Coexisting with Androgen Receptor Pathway prostate cancer.
Watanabe R; Miura N; Kurata M; Kitazawa R; Kikugawa T; Saika T
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240308
[TBL] [Abstract] [Full Text] [Related]
8. Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway.
Ji Y; Liu B; Chen L; Li A; Shen K; Su R; Zhang W; Zhu Y; Wang Q; Xue W
Cell Oncol (Dordr); 2023 Oct; 46(5):1445-1456. PubMed ID: 37120492
[TBL] [Abstract] [Full Text] [Related]
9. Stromal FAP Expression is Associated with MRI Visibility and Patient Survival in prostate cancer.
Pellinen T; Sandeman K; Blom S; Turkki R; Hemmes A; Välimäki K; Eineluoto J; Kenttämies A; Nordling S; Kallioniemi O; Rannikko A; Mirtti T
Cancer Res Commun; 2022 Mar; 2(3):172-181. PubMed ID: 36874403
[TBL] [Abstract] [Full Text] [Related]
10. Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of pten/p53-deficient prostate cancer.
Chaudagar K; Hieromnimon HM; Khurana R; Labadie B; Hirz T; Mei S; Hasan R; Shafran J; Kelley A; Apostolov E; Al-Eryani G; Harvey K; Rameshbabu S; Loyd M; Bynoe K; Drovetsky C; Solanki A; Markiewicz E; Zamora M; Fan X; Schürer S; Swarbrick A; Sykes DB; Patnaik A
Clin Cancer Res; 2023 May; 29(10):1952-1968. PubMed ID: 36862086
[TBL] [Abstract] [Full Text] [Related]
11. The Rate of Phosphatase and Tensin (pten) Gene Expression Loss in prostate cancer and its Link to Tumor Upgrading.
Gharib A; Aziminejad A; Pourmotahari F; Kazeminejad B; Soleimani M
Urol J; 2023 Dec; 20(6):403-407. PubMed ID: 36840446
[TBL] [Abstract] [Full Text] [Related]
12. ERG Status at the Margin Is Associated With Biochemical Recurrence After Radical prostatectomy With Positive Surgical Margins.
Salles DC; Mendes AA; Han M; Partin AW; Trock BJ; Jing Y; Lotan TL
Mod Pathol; 2023 Jul; 36(7):100147. PubMed ID: 36828362
[TBL] [Abstract] [Full Text] [Related]
13. AR and PI3K/AKT in prostate cancer: A Tale of Two Interconnected Pathways.
Tortorella E; Giantulli S; Sciarra A; Silvestri I
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768370
[TBL] [Abstract] [Full Text] [Related]
14. Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionation.
Wilkins A; Gusterson B; Tovey H; Griffin C; Stuttle C; Daley F; Corbishley CM; Dearnaley D; Hall E; Somaiah N
EBioMedicine; 2023 Feb; 88():104436. PubMed ID: 36708693
[TBL] [Abstract] [Full Text] [Related]
15. A machine learning framework develops a DNA replication stress model for predicting clinical outcomes and therapeutic vulnerability in primary prostate cancer.
Huang RH; Hong YK; Du H; Ke WQ; Lin BB; Li YL
J Transl Med; 2023 Jan; 21(1):20. PubMed ID: 36635710
[TBL] [Abstract] [Full Text] [Related]
16. Defining cellular population dynamics at single-cell resolution during prostate cancer progression.
Germanos AA; Arora S; Zheng Y; Goddard ET; Coleman IM; Ku AT; Wilkinson S; Song H; Brady NJ; Amezquita RA; Zager M; Long A; Yang YC; Bielas JH; Gottardo R; Rickman DS; Huang FW; Ghajar CM; Nelson PS; Sowalsky AG; Setty M; Hsieh AC
Elife; 2022 Dec; 11():. PubMed ID: 36511483
[TBL] [Abstract] [Full Text] [Related]
17. Correlation of expression of Major Vault Protein with androgen receptor and immune checkpoint protein B7-H3, and with poor prognosis in prostate cancer.
Nunes-Xavier CE; Emaldi M; Guldvik IJ; Ramberg H; Taskén KA; Mælandsmo GM; Fodstad Ø; Llarena R; Pulido R; López JI
Pathol Res Pract; 2023 Jan; 241():154243. PubMed ID: 36481650
[TBL] [Abstract] [Full Text] [Related]
18. High-Grade Desmoplastic Foamy Gland Prostatic Adenocarcinoma.
Gao G; Epstein JI
Arch Pathol Lab Med; 2023 Sep; 147(9):1039-1049. PubMed ID: 36399606
[TBL] [Abstract] [Full Text] [Related]
19. The prevalence and prognosis of next-generation therapeutic targets in metastatic castration-resistant prostate cancer.
Pan J; Zhao J; Ni X; Gan H; Wei Y; Wu J; Zhang T; Wang Q; Freedland SJ; Wang B; Song S; Ye D; Liu C; Zhu Y
Mol Oncol; 2022 Dec; 16(22):4011-4022. PubMed ID: 36209367
[TBL] [Abstract] [Full Text] [Related]
20. Tissue immunostaining of candidate prognostic proteins in metastatic and non-metastatic prostate cancer.
Pereira ÉR; Pinheiro LCL; Francelino AL; Miqueloto CA; Guembarovski AFML; de Oliveira KB; Fuganti PE; de Syllos Cólus IM; Guembarovski RL
J Cancer Res Clin Oncol; 2023 Feb; 149(2):567-577. PubMed ID: 36008689
[TBL] [Abstract] [Full Text] [Related]
[Next]
